TIM
ALXN

Thornburg Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Thornburg Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-97,490
Closed -$10.9M – 178
2020
Q2 		$10.9M Hold
97,490
– – 0.14% 100
2020
Q1 		$8.75M Buy
97,490
+104
+0.1% +$10.2K 0.13% 103
2019
Q4 		$10.5M Sell
97,386
-54
-0.1% -$5.78K 0.1% 116
2019
Q3 		$9.54M Sell
97,440
-160
-0.2% -$18K 0.09% 118
2019
Q2 		$12.8M Sell
97,600
-10,284
-10% -$1.33M 0.12% 106
2019
Q1 		$14.6M Sell
107,884
-24,817
-19% -$3.09M 0.14% 99
2018
Q4 		$12.9M Buy
132,701
+5
+0% +$591 0.13% 108
2018
Q3 		$18.4M Buy
132,696
+15,144
+13% +$1.9M 0.15% 104
2018
Q2 		$14.6M Buy
117,552
+378
+0.3% +$44.2K 0.11% 155
2018
Q1 		$13.1M Buy
117,174
+663
+0.6% +$79.2K 0.1% 158
2017
Q4 		$13.9M Buy
116,511
+14,911
+15% +$1.82M 0.1% 154
2017
Q3 		$14.3M Sell
101,600
-10
-0% -$1.36K 0.1% 150
2017
Q2 		$12.4M Sell
101,610
-16
-0% -$1.86K 0.09% 164
2017
Q1 		$12.3M Buy
101,626
+179
+0.2% +$23.1K 0.1% 158
2016
Q4 		$12.4M Sell
101,447
-31,576
-24% -$3.86M 0.1% 161
2016
Q3 		$16.3M Buy
133,023
+164
+0.1% +$21.1K 0.12% 141
2016
Q2 		$15.5M Buy
132,859
+8,688
+7% +$1.23M 0.12% 148
2016
Q1 		$17.3M Buy
124,171
+9,305
+8% +$1.37M 0.12% 156
2015
Q4 		$21.9M Buy
114,866
+244
+0.2% +$42.6K 0.14% 145
2015
Q3 		$17.9M Sell
114,622
-5,532
-5% -$1.01M 0.11% 155
2015
Q2 		$21.7M Hold
120,154
– – 0.13% 153
2015
Q1 		$20.8M Buy
120,154
+25,580
+27% +$4.63M 0.12% 169
2014
Q4 		$17.5M Sell
94,574
-18,241
-16% -$3.38M 0.09% 201
2014
Q3 		$18.7M Buy
112,815
+5,504
+5% +$904K 0.08% 193
2014
Q2 		$16.8M Buy
107,311
+18,266
+21% +$2.88M 0.07% 200
2014
Q1 		$13.5M Sell
89,045
-60,367
-40% -$9.6M 0.05% 206
2013
Q4 		$19.9M Sell
149,412
-14,022
-9% -$1.68M 0.08% 175
2013
Q3 		$19M Sell
163,434
-12,779
-7% -$1.4M 0.08% 177
2013
Q2 		$16.3M Buy
+176,213
New +$17M 0.07% 171

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thornburg Investment Management's ALXN Position: Q3 2020 in Review

Thornburg Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 97,490 shares — an estimated $10.9M sold.

Thornburg Investment Management first reported a position in ALXN in Q2 2013 and held it in 29 quarters. The position peaked at $21.9M in Q4 2015. 708 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Thornburg Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Thornburg Investment Management sold 97,490 Alexion Pharmaceuticals shares in Q3 2020, an estimated $10.9M.
  • Thornburg Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 29 quarters.
  • Thornburg Investment Management's Alexion Pharmaceuticals position peaked at $21.9M in Q4 2015.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Thornburg Investment Management's 13F filing for Q3 2020, filed 5 Nov 2020.